Needham & Company analyst Chad Messer reiterated a Buy rating and $57 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE